IRIS Accounts Production v23.3.0.418 SC165894 Board of Directors 1.6.22 31.5.23 31.5.23 0 0 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWhSC1658942022-05-31SC1658942023-05-31SC1658942022-06-012023-05-31SC1658942021-05-31SC1658942021-06-012022-05-31SC1658942022-05-31SC165894ns14:PoundSterlingns10:Original2022-06-012023-05-31SC165894ns10:Originalns10:Director12022-06-012023-05-31SC165894ns10:Original2022-06-012023-05-31SC165894ns10:Original2023-05-31SC165894ns10:Originalns10:PrivateLimitedCompanyLtd2022-06-012023-05-31SC165894ns10:Originalns10:SmallEntities2022-06-012023-05-31SC165894ns10:Originalns10:AuditExempt-NoAccountantsReport2022-06-012023-05-31SC165894ns10:Originalns10:SmallCompaniesRegimeForDirectorsReport2022-06-012023-05-31SC165894ns10:SmallCompaniesRegimeForAccountsns10:Original2022-06-012023-05-31SC165894ns10:Originalns10:FullAccounts2022-06-012023-05-31SC165894ns10:Original2021-06-012022-05-31SC165894ns10:Original2022-05-31SC165894ns10:Originalns5:CurrentFinancialInstruments2023-05-31SC165894ns10:Originalns5:CurrentFinancialInstruments2022-05-31SC165894ns5:ShareCapitalns10:Original2023-05-31SC165894ns5:ShareCapitalns10:Original2022-05-31SC165894ns10:Originalns5:CapitalRedemptionReserve2023-05-31SC165894ns10:Originalns5:CapitalRedemptionReserve2022-05-31SC165894ns10:Originalns5:FurtherSpecificReserve3ComponentTotalEquity2023-05-31SC165894ns10:Originalns5:FurtherSpecificReserve3ComponentTotalEquity2022-05-31SC165894ns10:Originalns5:RetainedEarningsAccumulatedLosses2023-05-31SC165894ns10:Originalns5:RetainedEarningsAccumulatedLosses2022-05-31SC165894ns10:PrivateLimitedCompanyLtd2022-06-012023-05-31SC165894ns10:Originalns5:CostValuation2022-05-31SC165894ns10:Originalns5:AdditionsToInvestments2023-05-31SC165894ns10:Originalns5:DisposalsRepaymentsInvestments2023-05-31SC165894ns10:Originalns5:RevaluationsIncreaseDecreaseInInvestments2023-05-31SC165894ns10:Originalns5:CostValuation2023-05-31
REGISTERED NUMBER: SC165894















COMPARATIVE RESEARCH LIMITED

UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MAY 2023






COMPARATIVE RESEARCH LIMITED (REGISTERED NUMBER: SC165894)






CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2023




Page

Balance Sheet 1

Notes to the Financial Statements 3


COMPARATIVE RESEARCH LIMITED (REGISTERED NUMBER: SC165894)

BALANCE SHEET
31 MAY 2023

2023 2022
Notes £    £    £    £   
FIXED ASSETS
Investments 4 250,244 287,626

CURRENT ASSETS
Cash at bank 22,216 18,324

CREDITORS
Amounts falling due within one year 5 7,174 5,794
NET CURRENT ASSETS 15,042 12,530
TOTAL ASSETS LESS CURRENT
LIABILITIES

265,286

300,156

PROVISIONS FOR LIABILITIES - 10,774
NET ASSETS 265,286 289,382

CAPITAL AND RESERVES
Called up share capital 50 50
Capital redemption reserve 40 40
Fair value reserve - 45,934
Retained earnings 265,196 243,358
SHAREHOLDERS' FUNDS 265,286 289,382

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 May 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 May 2023 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

COMPARATIVE RESEARCH LIMITED (REGISTERED NUMBER: SC165894)

BALANCE SHEET - continued
31 MAY 2023


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Profit and Loss Account has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 31 October 2023 and were signed on its behalf by:





Prof C R Rose BA DPhil FBA - Director


COMPARATIVE RESEARCH LIMITED (REGISTERED NUMBER: SC165894)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2023

1. STATUTORY INFORMATION

Comparative Research Limited, is a private company, limited by shares, registered in Scotland. The registered office is Caledonia House, 89 Seaward Street, Glasgow, G41 1HJ.

The financial statements are presented in Sterling (£).

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with the provisions of Section 1A "Small Entities" of the Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. There were no material departures from this standard. The financial statements have been prepared under the historical cost convention as modified by the revaluation of certain assets.

Judgements
The company considers on an annual basis the judgements that are made by management when applying its significant accounting policies that would have the most significant effect on amounts that are recognised in the financial statements. The directors consider there are no such significant judgements.

Turnover
Turnover represents the invoice value of services provided during the year. All turnover is attributable to the principal activity. The company's policy is to recognise income when substantively all the risks and rewards in connection with the service have been passed to the buyer.

Financial instruments
The company only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities like trade and other accounts receivable and payable and loans from related parties.

Debt instruments like loans and other accounts receivable and payable are initially measured at present value of the future payments and subsequently at amortised cost using the effective interest method. Debt instruments that are payable or receivable within one year, typically trade debtors and trade creditors, are measured, initially and subsequently, at the undiscounted amount of cash or other consideration expected to be paid or received.

Financial assets measured at cost and amortised cost are assessed at the end of each reporting period for evidence of impairment and if found, an impairment loss is recognised in profit or loss.

Financial liabilities are derecognised when the liability is extinguished, that is when the contractual obligation is discharged, cancelled or expires.

Cash and cash equivalents includes cash in hand, deposits held at call with banks, other short-term highly liquid investments with original maturities of three months or less and bank overdrafts. Bank overdrafts, when applicable, are shown within borrowings in current liabilities.


COMPARATIVE RESEARCH LIMITED (REGISTERED NUMBER: SC165894)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MAY 2023

2. ACCOUNTING POLICIES - continued
Taxation
Taxation represents the sum of tax currently payable and deferred tax. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.

The charge for taxation takes into account taxation deferred as a result of timing differences between the treatment of certain items for taxation and accounting purposes. In general, deferred taxation is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date. However, deferred tax assets are recognised only to the extent that the directors consider that it is more likely than not that there will be suitable taxable profits from which the future reversal of the underlying timing differences can be deducted. Deferred taxation is measured on a non-discounted basis at the average tax rates that would apply when the timing differences are expected to reverse, based on tax rates and laws that have been enacted by the balance sheet date.

With the exception of changes arising on the initial recognition of a business combination, the tax expense is presented either in profit or loss, other comprehensive income or statement of changes in equity depending on the transaction that resulted in the tax expense.

Deferred tax liabilities are presented within provisions for liabilities and deferred tax assets within debtors.

Fixed asset investments
Equity investments which are publicly traded and for which their fair value can be measured reliably are recognised initially at fair value which is normally the transaction price excluding any transaction costs. Subsequently, they are measured at fair value through profit and loss. Revaluation gains or losses arising on revaluation are accumulated in the profit and loss account reserve

Provisions
Provisions are recognised when the company has a legal or constructive obligation at the reporting date as a result of a past event, it is probable that the company will be required to settle the obligation and the amount of the obligation can be reliably estimated. Provisions are recognised at the best estimate of the amount required to settle the obligation at the reporting date.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was NIL (2022 - NIL).

4. FIXED ASSET INVESTMENTS
Other
investments
£   
COST OR VALUATION
At 1 June 2022 287,626
Additions 55,861
Disposals (93,113 )
Revaluations (130 )
At 31 May 2023 250,244
NET BOOK VALUE
At 31 May 2023 250,244
At 31 May 2022 287,626


COMPARATIVE RESEARCH LIMITED (REGISTERED NUMBER: SC165894)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MAY 2023

5. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£    £   
Other creditors 7,174 5,794

6. RELATED PARTY DISCLOSURES

At 31 May 2023, the balance due to the directors was £1,430 (2022: £1,430). The loan is interest free, unsecured and repayable on demand.